IRVING, Texas, April 15 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (OTC Bulletin Board: CARN) today announced that its wholly-owned subsidiary, DelSite Biotechnologies, Inc., entered into a non-exclusive technology evaluation agreement with a global pharmaceutical company for the purpose of evaluating DelSite's GelSite(R) polymer-based delivery technologies.
The goal of the program is to evaluate DelSite's parenteral technologies. DelSite has agreed to provide GelSite polymer and technical information concerning the optimal solubilization and mixing conditions. Terms of the agreement were not disclosed.
Carlton E. Turner, PhD, president and CEO of Carrington Laboratories and DelSite Biotechnologies, commented, "DelSite's technologies are novel and patent-protected, and we are dedicated to developing them for a wide range of applications. This agreement represents another highlight of increased interest in DelSite's technologies within the pharmaceutical industry."
DelSite is currently developing a nasal powder H5N1 influenza vaccine based on the GelVac(TM) nasal powder platform. Advantages of the GelVac vaccine delivery platform are: room temperature stability, needle-free administration, no adjuvant requirement, no preservative requirement, no cold-chain distribution, and induction of both systemic and mucosal immunity. DelSite plans to initiate a Phase I clinical study of the flu vaccine with the GelVac platform this summer.
GelSite polymer is a novel, naturally-occurring ionic carbohydrate
polymer that is capable of forming a gel upon contact with body fluids.
DelSite has developed three novel delivery platforms for various
applications: 1) GelVac nasal powder for nasal delivery of vaccines and
therapeutics; 2) GelSure(TM) for injectable delivery of therapeutics; and
3) GPDA(TM) depot adjuvant for vaccine applications. GPDA is a unique depot
adjuvant; unlike many current adjuvants, it does not stimulate immune cells
|SOURCE Carrington Laboratories, Inc.|
Copyright©2008 PR Newswire.
All rights reserved